| 79.86 -1.62 (-1.99%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 95.21 |
1-year : | 100.16 |
| Resists | First : | 81.52 |
Second : | 85.76 |
| Pivot price | 80.14 |
|||
| Supports | First : | 74.67 |
Second : | 62.12 |
| MAs | MA(5) : | 81.3  |
MA(20) : | 79.99 |
| MA(100) : | 73.78 |
MA(250) : | 65.31 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 58.7 |
D(3) : | 62.7 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 85.76 | Low : | 48.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LIVN ] has closed above bottom band by 47.3%. Bollinger Bands are 17.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 81.77 - 82.22 | 82.22 - 82.59 |
| Low: | 78.01 - 78.57 | 78.57 - 79.03 |
| Close: | 79.02 - 79.87 | 79.87 - 80.58 |
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Tue, 18 Aug 2026
LivaNova (NASDAQ:LIVN) Combines Strong Growth With a Promising Technical Breakout Setup - ChartMill
Sat, 15 Aug 2026
LivaNova PLC $LIVN Stake Lessened by Bank of America Corp DE - MarketBeat
Fri, 14 Aug 2026
Ahmet Tezel Executes Sell Order: Offloads $876K In LivaNova Stock - Benzinga
Thu, 13 Aug 2026
LivaNova (LIVN) executive exercises 12,692 SARs and disposes shares - stocktitan.net
Tue, 11 Aug 2026
LivaNova PLC (LIVN) employee stock rights lead to 2,675-share sale - stocktitan.net
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 55 (M) |
| Shares Float | 55 (M) |
| Held by Insiders | 0.4 (%) |
| Held by Institutions | 113.8 (%) |
| Shares Short | 4,090 (K) |
| Shares Short P.Month | 3,460 (K) |
| EPS | 3.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 22.05 |
| Profit Margin | 12.8 % |
| Operating Margin | 15.5 % |
| Return on Assets (ttm) | 5.2 % |
| Return on Equity (ttm) | 15.3 % |
| Qtrly Rev. Growth | 10.8 % |
| Gross Profit (p.s.) | 18.2 |
| Sales Per Share | 26.76 |
| EBITDA (p.s.) | 4.87 |
| Qtrly Earnings Growth | 287.7 % |
| Operating Cash Flow | 249 (M) |
| Levered Free Cash Flow | 65 (M) |
| PE Ratio | 23.55 |
| PEG Ratio | 0.9 |
| Price to Book value | 3.62 |
| Price to Sales | 2.98 |
| Price to Cash Flow | 17.59 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|